ReviewPharmaceutics2026
Copper Complexes: Emerging Micro- and Nanosystems for Dermatological Treatment.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of copper complexes as pharmacotherapy represents an emerging strategy with multiple therapeutic advantages, including their enhanced bioavailability, antimicrobial activity, and ability to participate in diverse cellular processes. These molecules, combined with micro- and nanosystems, offer an advanced approach to the sustained delivery of copper, optimizing its absorption while potentially reducing adverse effects. In this review, we highlight the application of copper complexes reported in recent studies for dermatological diseases and infection management. Furthermore, evidence indicates that copper promotes cell regeneration in wounds and burns, accelerating wound healing. However, their clinical translation requires careful consideration of copper homeostasis, as dysregulation may lead to oxidative stress and toxicity. In perspective, the combination of micro- and nanoformulations with specific copper complexes offers new opportunities for tailored therapies, as well as for the optimization of pharmacokinetics, positioning copper as a multifunctional therapeutic agent in regenerative and supplementation medicine. However, further investigation is required to establish safety, optimal dosing, and long-term effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.